Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: somatropin

First Posted Date: 2012-04-19

Last Posted Date: 2019-11-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 331

Registration Number: NCT01580605

Locations: 🇫🇷
Novo Nordisk Investigational Site, Lyon, France

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2012-04-18

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 321

Registration Number: NCT01579955

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2012-04-18

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 86

Registration Number: NCT01579968

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

French National Registry of Children Born Small for Gestational Age Treated With Somatropin

Completed

Conditions: Growth Disorder
Small for Gestational Age

Interventions: Drug: somatropin

First Posted Date: 2012-04-16

Last Posted Date: 2022-10-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 291

Registration Number: NCT01578135

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La Défense, France

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: semaglutide

First Posted Date: 2012-04-06

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 161

Registration Number: NCT01572753

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide
Drug: insulin

First Posted Date: 2012-04-06

Last Posted Date: 2018-02-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 257

Registration Number: NCT01572740

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2012-04-04

Last Posted Date: 2017-03-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 145

Registration Number: NCT01570751

Locations: 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin glargine
Drug: insulin degludec

First Posted Date: 2012-04-03

Last Posted Date: 2016-02-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01569841

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Minneapolis, Minnesota, United States

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Intracerebral Haemorrhage

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-29

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT01566786

Locations: 🇬🇧
Novo Nordisk Investigational Site, Newcastle, United Kingdom

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-03-29

Last Posted Date: 2016-10-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2223

Registration Number: NCT01565733

Locations: 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy